Gossamer Bio, Inc.

NASDAQ:GOSS

Biotechnology

Healthcare
$11.04 +3.24%

+$0.01 today

Market cap
$67.52M
Beta
2.04
P/E (TTM)
-0.2
EPS (TTM)
-$0.77
52W Low $0.11High $3.87

Volume 0.22M

Average 19.76M

Returns on capital

Gossamer Bio, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

138.8%

avg -227.0%

ROIC

-148.7%

avg 35.3%

ROA

-98.9%

avg -213.6%

Analysis

ROE is currently the strongest return metric at 138.8% versus its period average of -227.0%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Faheem Hasnain

Co-Founder, Chief Executive Officer, President & ChairmanUSD 908.45K68166<0.01%

Bryan Giraudo

Chief Operating Officer & Chief Financial OfficerUSD 676.74K5125<0.01%

Robert Smith

Chief Commercial OfficerUSD 663.71K57——

Christian Waage

Executive Vice President, Technical Operations & General CounselUSD 583.16K592.90M0.59%

Kelly Dawson

Senior Vice President & Program Team Lead————

Jean-Marie Bruey

Senior Vice President of Translational Medicine & Research————

Caryn L. Peterson

Chief Development Officer—67——

Deanna Weber

Executive Vice President of Human Resources————

Jeanine Anthony

Senior Vice President of Marketing————

Robert F. Roscigno

Senior Vice President of Clinical Development of Pulmonary Vascular Disease—60——

Conor O'Donovan

Senior Vice President of Regulatory Affairs————

Compensation is shown in the reported currency; data updated Nov 18, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Aug 24, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/AN/A
+41.3% (5yr)5 analysts
Net IncomeN/AN/AN/A
N/A5 analysts
EBITN/AN/AN/A
N/A5 analysts

Analysis

Forward estimates point to Revenue at +41.3% (5yr), giving you a quick read on expected growth from here.

Competitors

Who does Gossamer Bio, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about GOSS's management, answered from reported figures.

Who manages GOSS?

Gossamer Bio, Inc. (GOSS) lists 11 active executives. The top listed executive is Kelly Dawson, Senior Vice President & Program Team Lead.

Are GOSS insiders buying or selling?

Recent insider activity shows net selling of $2.35M.